Sage burns Parkinson's bridge, flunking first of 4 midphase tests for key prospect
by Fierce Biotech
Fierce Biotech— Sage Therapeutics has set a bad PRECEDENT for dalzanemdor. | Sage Therapeutics has set a bad PRECEDENT for dalzanemdor. The therapy failed to improve cognitive ability in a phase 2 Parkinson’s disease study, setting Sage off on the wrong foot at the start of a sequence of readouts that will define the future of the molecule.
Phandroid—Xiaomi could have the world’s first Snapdragon 8 Gen 4 smartphone. If the latest rumors are correct, Xiaomi could be the first brand in the world to launch a Snapdragon 8 Gen 4 smartphone.
@Marketplace—Workers who built Baltimore’s Key Bridge reflect on its reach in their lives. The ironworkers, painters and others who constructed the Francis Scott Key Bridge in the '70s thought it would outlive them.
The Independent—British patients test world’s first personalised mRNA jab for melanoma. Moderna and MSD are researching how their therapy could treat a wide range of cancers.